MaxLife review

The core product pages describe three-month starter purchases, not separate monthly starter debits. Semaglutide is $267 upfront, equivalent to $89 per month for that introduction, then $155/month. Tirzepatide is $360 upfront, equivalent to $120 per month, then $195/month. Separate monthly cards advertise $155 and $195. Compare the cash due now, the continuing charge and the actual supplied medication together. These prices do not verify your dose, vial quantity, taxes or selected invoice. General terms also allow an offer-specific early termination fee for a preset commitment, so ask how the starter can be ended and whether any balance remains due. A lower monthly equivalent is useful for budgeting, but it should not be mistaken for monthly collection or proof that all prepaid medication becomes refundable when treatment stops.

MaxLife advertises prescription medication, supplies and priority delivery within the program. Its FAQ says fulfillment can be monthly or every 90 days depending on the billing period and prescribed dose. Confirm the preparation, concentration, quantity, usable supply and accessories for your actual prescription. The product pages' free-overnight-shipping wording does not establish arrival the day after signing up. The FAQ separately gives typical pharmacy processing of two to three business days when medication is in stock, and terms do not guarantee a particular arrival time. Insulated packaging with ice and needles is described. Obtain actual storage and handling instructions from the pharmacist rather than treating general time-in-box marketing as proof that a particular temperature excursion is acceptable. For an error, delay or damage concern, ask the responsible pharmacy and support team which remedy applies before assuming an automatic cash refund.

MaxLife Technologies Inc. describes a patient-management platform that works with independent clinicians and pharmacies. Its terms distinguish that customer relationship from the provider-patient relationship with the treating medical group. The assigned clinician and practice are not established by a general physician-guided description. The pharmacy network is more specific: the FAQ names ten partners, including Dirx, Southend, Red Rock, VLS and NewLife Rx, and says dispensing varies by location, prescription and availability. That disclosure corrects the impression that no pharmacy is named, but it does not assign any particular facility to you or independently verify a current license. Ask for the actual dispensing name and address on your prescription and shipping documentation, and confirm which medical practice handles follow-up. Pharmacy partners and the platform should not be treated as interchangeable clinical or manufacturing entities.

The program advertises ongoing provider messaging, dose adjustments and side-effect support, with audiovisual visits when state requirements call for them. That does not establish a fixed number of live appointments or a funded baseline and repeat-laboratory allowance. Ask which tests the clinician requires, whether existing results can be used, and which party bills for collection and analysis. Also ask how refill review works and whether a higher-dose prescription changes the membership price. The FAQ says MaxLife serves all 50 states, while the general terms qualify some services by location. Confirm the selected medication and the clinician's and pharmacy's ability to serve your physical location and address. National marketing alone does not establish availability of every formulation. HSA or FSA eligibility is also something to confirm with your own administrator, rather than a guarantee that the plan will reimburse the advertised bundle.

The September 2024 terms require email notice 30 days before the intended cancellation date, and the FAQ describes notice at least 30 days before the next billing period. Renewals otherwise continue automatically at the selected frequency. Ordinary subscription payments and partly used periods are nonrefundable; shipped medication cannot be canceled or returned for reuse. Terms separately allow refunds for ineligibility and company-canceled billed orders, which should not be treated as unconditional voluntary-cancellation rights. A preset commitment can have an early termination fee specified in its offer, so obtain the selected agreement before prepaying. The terms also contain different descriptions of continued paid-period access and possible immediate deactivation; clarify how care and prescription access will continue. Keep the effective cancellation date in writing. Advertised results and price-match guarantees need their own complete conditions before being relied on as a remedy.

FDA's February 2026 warning letter, number 721453, names MaxLife Technologies Inc. dba Maxlife and concerns compounded semaglutide and tirzepatide marketing. It challenged pictured labels suggesting MaxLife itself compounded the drugs, plus claims implying FDA approval, generic status or clinical evaluation of the compounds. It does not establish contamination of a particular patient's prescription or a finding against whichever partner pharmacy fills your order. MaxLife's August 2026 status page reports a written response and corrective actions, including clearer role and compounding disclosures. The company also says FDA had not formally closed the matter as of that update. An FDA closeout was not established in this review, so neither resolution nor a new enforcement action should be inferred. Read the current disclosures alongside the warning; company-reported changes are not the same as a regulator accepting them.